Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus.

Annals of the New York Academy of Sciences - 18 Jun 1999

Burcelin R, Rolland E, Dolci W, Germain S, Carrel V, Thorens B

Abstract excerpt

Non-insulin-dependent, or type II, diabetes mellitus is characterized by a progressive impairment of glucose-induced insulin secretion by pancreatic beta cells and by a relative decreased sensitivity of target tissues to the action of this hormone. About one third of type II diabetic patients are treated with oral hypoglycemic agents to stimulate insulin secretion. These drugs however risk inducing hypoglycemia...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes Mellitus, Type 2
Share to Genetic Engineering

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Glucagon

Share to Glucagon-Like Peptide 1

Share to Membranes, Artificial

Share to Peptide Fragments

Share to Protein Precursors

Source

Identifiers

PMID: 10415574
DOI: 10.1111/j.1749-6632.1999.tb08510.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus.PMID 10415574Read ↗

Treatment of diabetes mellitus with microencapsulated fetal human liver (FH-B-TPN) engineered cells.Semantic proximity Read ↗

Oral GLP-1 Analogue Ameliorates Obesity-Induced Diabetes In Db/Db MouseSemantic proximity Read ↗

Reversal of diabetes following transplantation of an insulin-secreting human liver cell line: Melligen cellsSemantic proximity Read ↗

GLP-1-mediated gene therapy approaches for diabetes treatmentSemantic proximity Read ↗

Genetically Encoding a Lipidated Amino Acid for Extension of Protein Half‐Life in vivoSemantic proximity Read ↗

Beta‐cell replacement strategies for diabetesSemantic proximity Read ↗

Pluripotent stem cell replacement approaches to treat type 1 diabetes.Semantic proximity Read ↗

Gut delivery of pentameric GLP-1 using genetically engineered <i>Bacillus subtilis</i>Semantic proximity Read ↗

Oral delivery of GLP-1R agonist by an engineered probiotic yeast strain has anti-obesity effects in miceSemantic proximity Read ↗

Islet-Like Structures Generated In Vitro from Adult Human Liver Stem Cells Revert Hyperglycemia in Diabetic SCID Mice.Semantic proximity Read ↗

Gene and Cell-Replacement Therapy in the Treatment of Type 1 DiabetesSemantic proximity Read ↗

Recent Advances in the Development of Bioartificial Pancreas Using 3D Bioprinting for the Treatment of Type 1 Diabetes: A ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.